Rhumbline Advisers Has $1.74 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Rhumbline Advisers increased its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 0.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 236,681 shares of the company’s stock after acquiring an additional 1,288 shares during the quarter. Rhumbline Advisers owned about 0.17% of Vir Biotechnology worth $1,737,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. KBC Group NV increased its holdings in Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock valued at $66,000 after buying an additional 5,177 shares during the period. Captrust Financial Advisors bought a new position in shares of Vir Biotechnology during the third quarter valued at $118,000. Quarry LP increased its position in shares of Vir Biotechnology by 901.8% during the 3rd quarter. Quarry LP now owns 17,000 shares of the company’s stock worth $127,000 after purchasing an additional 15,303 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Vir Biotechnology in the 3rd quarter worth approximately $138,000. Finally, Intech Investment Management LLC acquired a new stake in Vir Biotechnology during the 3rd quarter valued at $191,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Vir Biotechnology

In other Vir Biotechnology news, Director George A. Scangos sold 10,964 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the transaction, the director now owns 708,295 shares of the company’s stock, valued at approximately $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Verneuil Vanina De sold 7,373 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the transaction, the executive vice president now owns 79,460 shares of the company’s stock, valued at $726,264.40. This trade represents a 8.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,859 shares of company stock worth $326,458 in the last quarter. Corporate insiders own 15.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, February 28th. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. Leerink Partners upped their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a research report on Thursday, February 27th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research note on Thursday, January 9th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.67.

Vir Biotechnology Trading Up 3.5 %

Shares of VIR opened at $8.20 on Wednesday. The stock has a market cap of $1.13 billion, a P/E ratio of -2.09 and a beta of 0.64. Vir Biotechnology, Inc. has a 1 year low of $6.56 and a 1 year high of $14.45. The stock’s 50-day moving average price is $9.48 and its two-hundred day moving average price is $8.49.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. The firm had revenue of $12.37 million during the quarter, compared to analysts’ expectations of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. As a group, equities analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).